Nervous Disorder TRIZ Cases

Hyperbranched dendritic nanocarriers encapsulate cannabis active agents to enhance transdermal and transmucosal bioavailability.

Codon adaptation of expression cassettes reduces toxic agent exposure and shortens development time.

Anti-Gremlin-1 antibody blocks Gremlin-1 binding to cancer cells, inhibiting migration and proliferation independent of BMP or VEGFR2 pathways.

Specific peptide ligands bind selectively to prion proteins for targeted detection and removal from biological samples.

R-P88 metabolite enables faster titration and reduced orthostatic hypotension in psychiatric disorders.

Engineered monoclonal antibodies neutralize neurotoxicity by targeting unique conformational structures of amyloid beta oligomers.

Antibodies targeting semaphorin-4D resolve the angiogenesis-neural regeneration trade-off by blocking inhibitory signaling to improve brain volume.

Solid-phase synthesis of the 15-amino acid SVHRSP peptide preserves scorpion venom pharmacological activity.

Modifying phorbol ester structures reduces tumor-promoting activity while maintaining therapeutic effectiveness against HIV and cancer.

Acetone-water crystallization produces donepezil pamoate crystal form A, resolving severe agglomeration and poor fluidity from conventional solvent methods.

Polysorbate 20 and sucrose stabilize anti-hNGF antibodies against aggregation during storage while maintaining low viscosity for administration.

Parenteral omega-3 fatty acid vehicle enhances drug bioavailability and therapeutic efficacy through rapid plasma membrane incorporation.

Engineered FcRn antagonists bind receptors to lower circulating antibody concentrations, treating autoimmune diseases by shortening IgG half-life.

Chimeric human complement C3 proteins incorporate Cobra Venom Factor domains to form stable convertases.

AAV vectors deliver miRNA scaffolds to oligodendrocytes, reducing pathological gene expression to treat myelin disorders.

ATL_5262 antibodies compete with Netrin-1 for UNC5C binding, reducing apoptosis and addressing limited efficacy of current Alzheimer's therapies.

Human anti-HER3 antibody binds extracellular domain to inhibit HER3 activity.

Liver-directed AAV vectors expressing MOG and PLP induce antigen-specific Tregs, suppressing CNS inflammation without requiring HLA-MHC epitope identification.

Monoclonal antibodies bind sphingosine-1-phosphate to neutralize bioactive lipids, reducing aberrant immune responses and tissue damage in autoimmune disorders.

An anti-tau antibody binds specifically to the acetylated 280th lysine fragment of tau protein.

A choline and succinate composition supports one-carbon metabolism through a defined molar ratio.

Covalent hydrocodone conjugates with aryl carboxylic acids prevent abuse by requiring enzymatic breakdown for active release.

Soybean-derived peptide conjugates reduce immobility time to treat mood disorders with inadequate current therapies.

Screening HTRA1 promoter mutations enables early Alzheimer's diagnosis and guides tau protease therapies, resolving diagnostic reliability gaps.

Formula I compounds modify lipophilicity to cross the blood-brain barrier, addressing limited efficacy of existing treatments for neurodegenerative diseases.

Monoclonal antibodies bind nerve growth factor to block pain signaling, avoiding opioid addiction risks.

Spider venom peptides inhibit ASIC1a channels to reduce infarct size, offering a broader therapeutic window than thrombolytics.

Acetyl-Asp-Lys-Arg-Arg-amide tetrapeptide normalizes brain chemistry and improves cognitive functions in Alzheimer's models.

Reduced TNFAIP3 levels in blood samples serve as a biomarker to detect myelin oligodendrocyte glycoprotein antibody-associated disease relapses.

Fyn tyrosine kinase inhibitors target the Fyn-PKCδ pathway to reduce neuroinflammation and treat refractory epilepsy resistant to conventional drugs.

Antibodies targeting CAPRIN-1 proteins impair cancer cells, reducing side effects from non-specific targeting.

A 1:1:1 THC:CBC:CBD formulation reduces pain sensitivity and improves mobility through cannabinoid receptor activation.

Intranasal insulin and glutathione bypass the blood-brain barrier to improve symptom management while reducing systemic side effects.

Paraxanthine compositions replace caffeine to provide energy without inducing anxiety or nervousness.

Segmented gamma-hydroxybutyrate formulation prevents pharmacokinetic interactions with divalproex sodium, maintaining therapeutic efficacy for narcolepsy.

A Formula I compound modulates MET and VEGF signaling pathways to treat metastatic bone cancer.

Segmenting gp120 into specific peptide immunogens elicits broad neutralizing antibodies against diverse HIV strains, overcoming narrow vaccine efficacy.

PAMAM dendrimer nanoparticles overcome the blood-brain barrier to distribute drugs throughout brain tissue.

A brain-targeted nanogel delivers PD-L1 antibodies across the blood-brain barrier using specific ligands.

A universal neuromodulation system combines deep brain and transcranial stimulation to treat depression when medications fail.

Formula II compounds inhibit cathepsin S to treat autoimmune disorders while reducing cytotoxicity.

Purified Amanita muscaria extracts isolate muscimol to modulate neurotransmission, resolving toxicity from ibotenic acid and heavy metal contaminants.

7α,11β-dihydroxy-6α-ethyl-5β-cholan-24-oic acid activates the Farnesoid X receptor to treat liver disorders.

Selective oxytocin receptor agonists reduce hyperphagia and obsessive-compulsive behaviors in patients.

This herbal composition inhibits glutamate receptor activity to manage ADHD symptoms without the dependence risks associated with conventional central nervous system stimulants.

Pre-conditioned neural stem cells integrate into host tissue to produce specific neurotransmitters, overcoming low survival rates and limited differentiation.

Passion fruit extracts reduce oxidative stress and glutamate toxicity to prevent neural cell degeneration.

Modified aryl heteroaryl compounds alleviate and prevent anxiety severity across mild to severe cases.

A compound preparation of traditional Chinese medicines promotes nerve growth and myelination.